Vor Biopharma and MaxCyte announce clinical and commercial licence agreement for engineered hematopoietic stem cells to treat cancer

Image: Vor Biopharma and MaxCyte have announced clinical and commercial licence agreement for engineered hematopoietic stem cells to treat cancer. Photo: courtesy of Arek Socha from Pixabay.